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ABSTRACT 
 
The affinity engineering is a key step to increase the therapeutic efficacy of 
monoclonal antibodies (mAbs). Yeast surface display (YSD) is the most 
widely used and powerful affinity maturation approach, allowing for the 
achievement of low picomolar antibody binding affinities. A great number of 
mAbs approved for clinics are used in cancer immunotherapy, for the 
targeting of either tumor neoantigens or immune checkpoint components; this 
second approach aims to re-activate the T cell-mediated anti-tumor 
immunity, which is often impaired by cancer cells through several immune 
escape mechanisms. In this study, we describe an optimization of the YSD 
methodology, applied to the generation of potentially therapeutic high 
affinity single chain antibody fragments (scFvs) targeting PD-L1, an immune 
checkpoint component which is often upregulated on cancer cell surface. We 
generated two different yeast libraries with high mutant frequency and 
diversity, by multi-step random mutagenesis of the heavy chain variable 
region CDR3 of an anti PD-L1 scFv. By panning the libraries against soluble 
PD-L1 antigen and through few sequential rounds of fluorescence-activated 
cell sorting (FACS), we quickly isolated mutated yeast clones with conserved 
mutation hotspots. Among these scFv-yeast clones, 6 of them were enriched 
and showed a 6,3- to 9,8-fold affinity improvement compared with the 
parental one. These scFvs maintained some binding improvement also when 
converted into IgGs and tested on PD-L1 protein showed on the plasma 
membrane of human activated lymphocytes. For this reason, these novel 
antibodies could be good candidates for an antibody-based, PD-L1-targeted 
cancer immunotherapy. 
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1. INTRODUCTION 
 
1.1.  Antibodies as therapeutics 
Monoclonal antibodies (mAbs) are widely used as therapeutics in various 
kinds of medical applications, such as autoimmune diseases (Chan et al, 
2010), infectious diseases (Casadevall et al, 2004; Hey, 2015), post-
transplantation immunosuppressive regimens (Mahmud et al, 2010) and 
cancer (Carter, 2001).  
Since 1986, 74 mAbs have been approved by Food and Drug Administration 
(FDA) (https://www.accessdata.fda.gov/scripts/cder/daf/) and hundreds are in 
clinical trials with 50 of them undergoing late-stage clinical studies (Reichert, 
2017).  
Although most of the therapeutic mAbs are whole antibodies (murine, 
chimeric, humanized or fully human), alternative antibody formats consisting  
in antibody fragments or single antibody domains are emerging; thanks to 
their smaller size, these non-canonical antibodies overcome some 
pharmacokinetic issues such as tissue penetration. This class of molecules 
includes single chain variable fragments (scFv), formed by an heavy and a 
light chain variable domain (VH and VL respectively), covalently linked to 
each other; derivatives of scFvs (diabodies, tribodies, tetrabodies); antigen-
binding fragments, (Fab, mono- or bi-specific); minibodies, i.e. 
immunoglobulins lacking the first and second constant domains of heavy 
chains (CH1 and CH2) or even single VH domains (Holliger et al, 2005).  
Whatever the antibody format, all these molecules can be engineered to reach 
the desired pharmacological effect by improving various properties, such as 
affinity, solubility and stability in buffer formulations suitable for injection in 
humans, pharmacokinetic properties, immunogenicity and effector functions 
(if the molecule retains any effector domain). To improve the binding 
characteristics of an antibody, the variable region is usually engineered and it 
is not unusual that manipulating this region has an impact on all the other 
above properties too; on the contrary, changes in the constant region or 
crystallizable fragment (Fc) usually affect only the antibody effector 
functions (Igawa et al, 2011). 
 
1.2.  In vivo antibody affinity maturation  
The binding of an antibody to its antigen is a reversible process in which the 
speed of association/dissociation depends on two kinds of forces. The first 
one is called affinity and it measures the binding strength of a single antibody 
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to its ligand partner; the affinity is measured through the equilibrium 
dissociation constant (Kd) that is a ratio of the antibody dissociation rate 
(koff) to the antibody association rate (kon) and it is inversely correlated with 
affinity. The other force is called avidity and plays a key role in the formation 
of great immunocomplexes in which many antibodies bind simultaneously to 
many antigen molecules; for this reason, avidity measures the overall binding 
strength resulting from the contribution of each antibody binding site 
(Rudnick et al, 2009; Oda et al, 2004).  
Antibodies developed for clinics should have very high affinities for their 
targets, ensuring a more effective therapy (for example the ability of the 
antibody to recognize very low concentrations of its target) and allowing for 
a reduction in the dosage or in the number and frequency of administrations, 
mainly thanks to longer dissociation rates. Thus, a newly discovered antibody 
(called “lead antibody”) is frequently engineered to improve its affinity 
through a process called affinity maturation. The principles underlying this 
process are the same as those used in vivo by B cells during the immune 
response (Chowdhury et al, 1999).  
Each naïve B lymphocyte, resident in lymph node follicles, expresses a 
different B cell receptor (BCR) also called immunoglobulin (Ig), able to 
recognize a specific and unique foreign antigen. The diversification of the B 
cell receptor repertoire is achieved during B cell differentiation through 
somatic recombination of three different kinds of genic segments, called V, D 
and J respectively, each present in many different copies in the human 
genome. Once rearranged in a specific combination, these fragments form the 
complete and unique sequence of the variable region of an antibody, enabling 
it to specifically recognize a single antigen (Roth, 2014). All these Igs share 
the same Fc region (M isotype) and, upon antigen stimulation, they are 
produced in a soluble format in order to neutralize the foreign antigen 
circulating in the blood. At the beginning of the B cell response, IgMs show a 
very weak binding strength for their own antigens (their affinities range 
between 10^-4 and 10^-6 mol/L), but when secreted, they are grouped into 
pentameric complexes having a high avidity for the antigen that is sufficient 
to ensure a first-line and effective protection. In the meantime, the B cell 
receptor locus undergoes various somatic rearrangements, called somatic 
hypermutation (SHM) and class switch recombination, aimed to produce Igs 
with the same antigen specificity, but improved affinity and different effector 
functions (IgG, IgA, IgE) (Stavnezer et al, 2008), allowing for a more 
effective and long lasting protection.  
The main responsible of the genetic alterations at the B cell receptor locus is 
the DNA-editing enzyme activation-induced cytidine deaminase (AID). This 
protein, whose expression is induced in B cells by antigenic stimulation, 
converts deoxycytidine to deoxyuridine, generating mismatches between 
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deoxyuridine and guanine that activate the error-prone mechanisms of DNA 
repair. In this way, point mutations or indels are introduced in the site of 
deamination during B cell division with a frequency that is 105-106-fold 
higher than the mutation rate which normally occurs during DNA replication. 
These mutations fall in the sequences encoding for the heavy and light chain 
variable regions, with mutation hotspots in the complementarity-determining 
regions (CDRs), i.e. the short amino acid loops directly contacting the 
antigen (Di Noia et al, 2007; Maul et al, 2010). Only a small fraction of these 
mutations (about 20%) affects affinity; the B cells expressing Igs with lower 
affinity for the antigen die for apoptosis (a process called negative selection) 
due to the lack of antigen binding, which represents the stimulus for their 
survival and proliferation. On the contrary, the B cells in which a high 
affinity Ig has been generated by SHM are positively selected for 
proliferation and differentiate into antibody-secreting plasma cells or long-
living memory B cells; alternatively, they undergo another cycle of 
mutagenesis in order to further increase Ig affinity as the immune response 
goes on (Gatto et al, 2010). The in vivo affinity maturation is able to generate 
antibodies with affinities in the picomolar range (10-10 mol/L) (Batista et al, 
1998; Foote et al, 1995) (fig. 1). 
 
 
 
 
 
Fig. 1: schematic representation of in vivo antibody affinity maturation. 
Pink stripes represent the CDRs of the VH or VL, whereas colored bars 
indicate point mutations. At the beginning of the B cell response, they are 
interspersed throughout the variable region; while the immune response goes 
on, more mutations accumulate in this locus, but only B cells in which they 
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increase the antibody affinity for the antigen can survive. Mutations are more 
frequent in the CDRs.  
 
 
1.3.  In vitro antibody affinity maturation  
In vitro affinity maturation mimics the events that happen in vivo: the 
sequence of the lead antibody variable region is randomly mutated to 
generate a highly diversified repertoire of antibodies with different affinities 
for the same antigen; then the antibodies showing the highest affinity for the 
target are selected among this heterogeneous population. These in vitro 
technologies have successfully generated antibodies with low picomolar or 
even femtomolar affinities for their target (from 10-10 to 10-15 mol/L) (Boder 
et al, 2000). The most common approaches to generate these antibody 
repertoires starting from the parental sequence are random mutagenesis, 
randomization of targeted residues using degenerate oligonucleotides, chain 
shuffling and in silico approaches.  
The random mutagenesis allows the generation of a broad range of variants 
of the parental antibody in which each residue could be potentially mutated; 
mutations are introduced through error-prone PCR or E. coli mutator 
bacterial strains, which are defective in DNA repair (Rasila et al, 2009).  
The error-prone PCR (ep-PCR) has the advantage to select for a specific 
antibody region in which mutations have to be introduced; the mutagenesis 
can be targeted to the whole variable region or only to VH or VL or to more 
restricted sequences, most commonly one or more CDRs. The ep-PCR 
system is based on an error-prone Taq polymerase which, lacking 
proofreading activity, randomly inserts point mutations in the target 
sequences with high frequency. Nevertheless, at the amino acid level not all 
the substitutions have the same chance to occur at any position; this happens 
when two or even all the three nucleotides of the same codon have to be 
changed simultaneously to encode for a given amino acid (Neylon, 2004).       
Randomization of targeted residues exploits degenerated oligonucleotides 
and restricts the mutagenesis only to specific amino acid residues. The target 
positions, generally identified by alanine-scanning, are modified with a series 
of ad-hoc PCR primers, in order to generate all possible amino acid 
substitutions (Ko et al, 2015). 
Chain shuffling consists in combining a repertoire of VH with a fixed VL (or 
vice versa), but chain shuffling of the CDRs only are also described 
(Yoshinaga et al, 2008; Marks, 2004). In more recent works, in silico 
approaches have also been successfully used; these methods are based on 
computational design and structure predictions of antibody-antigen 
interactions (Clark et al, 2006; Barderas et al, 2008). 
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Once new repertoires have been generated, the antibodies with improved 
affinity can be selected by means of display methods, which are grouped into 
cell-based and cell free systems. 
In cell-based approaches, the sequence variants of the parental antibody are 
showed (displayed) on the cell surface of yeasts (yeast surface display), 
phages (phage display), bacteria (E. coli surface display) or mammalian cells 
(commonly HEK293, CHO or B-lineage cells) (Doerner et al, 2014). The 
antibodies are fused to a proper protein of the cell surface and subsequently 
panned against the antigen of interest, provided in the format of soluble 
protein or in the mammalian cell surface context (whole cells or detergent-
solubilized cell membranes) (Tillotson et al, 2013), if it is a membrane 
protein. Various cycles of panning are usually performed (up to 4 or 5), 
increasing the stringency of selection at each round in order to isolate and 
enrich the clones displaying the antibodies with the improved affinity; the 
stringency can be typically increased by a reduction of the antigen 
concentrations (Chao et al, 2006;). However, in some cases only one 
selection step has been sufficient to isolate high affinity variants.  
The scFvs are the most commonly displayed antibody format due to their 
little size and the absence of post-translational modifications, which allows 
the production and display both in prokaryotes and eukaryotes. Fab 
fragments or full length Igs can be also displayed and in the case of whole 
antibodies, which need for post-translational modifications, eukaryotic 
systems are necessarily required (Doerner et al, 2014).  
In cell free systems, which include ribosome display and mRNA display, the 
library generation is achieved by in vitro translation of the DNA, using 
ribosome preparations instead of the cellular translation machinery; 
chaperones and other enzymes are added to the reaction to help the proper 
polypeptide folding (Lipovsek et al, 2004).   
 
 
1.4.  Affinity maturation by yeast surface display (YSD)  
YSD is the most widely used affinity maturation platform, combining a lot of 
advantages compared with the other methods (Chao et al, 2006; Gera et al, 
2013). Firstly, unlike phages and bacteria, yeasts are eukaryotic cells, 
consequently the displayed proteins are properly folded by the endoplasmic 
reticulum chaperones and receive all the post-translational modifications 
necessary for their function.  
In addition, the generation of the libraries is easier compared to all the other 
systems because it is achieved by in vivo yeast recombination, which is more 
efficient than in vitro cloning by ligation, used in the other display systems. 
Once generated by mutagenesis, the sequence variants are co-transformed 
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with a proper yeast expression plasmid, which remains episomal after 
recombination. By optimization of the vector-insert ratio, a maximum 
transformation efficiency of about 109 colony forming units can be easily 
obtained routinely (Benatuil et al, 2010), meaning that at most 109 different 
sequences can be found in a yeast library. Although, a higher theoretical 
diversity can be obtained by other approaches (up to 1011 by phage display or 
even 1014 by cell-free systems), a repertoire of 109 is considered more than 
enough when performing affinity maturation (Chao et al, 2006; Gera et al, 
2013; Boder et al, 2000). 
However, the main advantage of YSD is represented by the possibility to use 
flow cytometry to select for clones with improved affinity. The use of 
fluorescence allows a real-time quantification of the protein expression level 
and the antigen binding strength directly during the screening process. This 
detection method is very powerful to discriminate even little differences in 
the binding properties of the antibody variants.  
Saccharomyces cerevisiae and, more recently, Pichia pastoris are the most 
commonly used species for YSD. Various yeast cell wall proteins are suitable 
as anchors for display, in particular the a- and α- agglutinins, the flocculin 
Flo1p and the Pir family proteins (Pir1-4) (Pepper et al, 2008). The most 
frequently used yeast strain is called EBY100; it has been generated through 
the genetic engineering of the chromosome of S. Cerevisiae BJ5465 strain 
and its display system is based on the a-agglutinin Aga (Chao G et al, 2006). 
Aga is a yeast mating protein with a dimeric structure, in which one subunit 
(Aga1p) is covalently linked to the cell wall through a 
glycosylphosphatidylinositol (GPI) anchor, while the other one (Aga2p) is 
linked to Aga1p by two disulfide bonds (fig. 2). Aga1p sequence is stably 
integrated into the yeast genome, whereas Aga2p gene is encoded by the 
episomal display plasmid and it is fused in frame with the antibody encoding 
sequences, at either their N or C-terminus; both Aga1p and Aga2p-antibody 
expression is driven by a galactose-inducible promoter; this system allows a 
fine tuning of the display level, up to 5x104 molecules/cell. EBY100 genome 
has also been modified through the insertion of mutations in some genes 
involved in the synthesis of certain nucleotides and amino acids, rendering 
this strain unable to grow in absence of these substrates (the so-called 
auxothrophic strains). These missing proteins are provided by the plasmid 
used for recombination, consequently only yeasts in which the recombination 
has occurred are positively selected for growth in a medium deprived of the 
above nutrients.  
The yeast-antigen complexes are detected using a two-color labeling with 
fluorescent antibodies (fig. 2 and 3) (Chao et al, 2006). One antibody 
(fluorescence 1, FL1 in fig. 2 and 3) recognizes a tag located at the N or C-
terminus of the Aga2p fusion proteins expressed on yeast surface; therefore, 
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this antibody is used to distinguish the displaying yeasts from the non-
displaying ones that will appear as two distinct cell populations (a positive 
and a negative one, respectively) in a typical flow cytometry dot plot (lower 
right and lower left quadrant, respectively, in fig. 3). As result, the 
fluorescence intensity of the displaying yeasts depends on how many Aga-
antibody fusion proteins are showed on their surface. The advantage of using 
a C-term tag is that only yeasts displaying full length molecules can be 
detected and then included into the selection. The second antibody 
(fluorescence 2, FL2 in fig. 2 and 3) recognizes the soluble antigen or a 
surface marker of the antigen expressing cells. As a result, the displaying 
yeasts that bind the antigen are positive for both the fluorescences (upper 
right quadrant in fig. 3). Also in this case, the number of antigen molecules 
bound to each cell determines its fluorescence intensity in FL2 channel.  
Fluorescence-activated cell sorting (FACS) is used to isolate the best binder 
yeasts. The cells of interest are identified directly on the plot before the 
isolation, by drawing a diagonal gating in the quadrant of the double positive 
fluorescent population (Gera N et al, 2013) and then sorted for the separation 
from the library. The diagonal gate should include those yeast clones that, for 
each level of scfv display along the abscissa, bound the highest number of 
antigen molecules (fig. 3).  
The enrichment of the yeasts with a better antigen binding compared with the 
parental antibody is obtained through repeated sortings, typically three to 
five, in which the selection stringency is progressively increased using lower 
antigen concentrations at each selection step (Chao et al, 2006). 
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Fig. 2: Schematic representation of the detection system of the scfv-
antigen complex by flow cytometry. The scfv is fused to the Aga2p subunit 
(at its N-terminus in this case) and this fusion protein carries a terminal tag 
(an example of a C-term tag is shown, in orange). The chimeric protein is 
covalently linked to Aga1p through two disulfide bonds and anchored to the 
yeast cell wall (purple) thanks to Aga1p GPI anchor (showed in red). The 
protein display is detected by an anti-tag fluorescent antibody (FL1). If the 
scfv binds to the antigen (in yellow), the complex is labelled with a second 
antibody (FL2), giving double fluorescent signal that can be detected by flow 
cytometry. 
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Fig. 3: typical flow cytometry dot plot in a YSD experiment. This example 
refers to a yeast library labelled with the two antibodies indicated in fig. 2 
(FL1 and FL2) and shows the different cell populations (here represented by 
different colors), distinguished on the basis of their fluorescence level. 
Antigen binding cells are in the double positive quadrant (blue, Q1-UR 
quadrant) and are sorted by a typical diagonal gating strategy, here 
represented by the diagonal P4 gate (purple). In Q1-LR (single positive for 
FL1) displaying cells unable to bind the antigen are located, while the non-
displaying yeasts appear in the double negative quadrant (grey, Q1-LL). 
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1.5.  Antibodies with potential therapeutic application, isolated by 
YSD  
 
A lot of examples of antibody affinity engineering through yeast display are 
reported in literature. The most surprising result is that obtained by Boder et 
al in 2000. They isolated some anti-fluorescein antibody fragments with an 
affinity of 48 fM, starting from a parental scFv with an affinity of 0,7 nM. 
These scFvs were isolated after four subsequent cycles of affinity maturation 
from libraries with complexities between 105 and 107. Their affinity is the 
highest so far reported for an engineered protein, but they are not for clinical 
use. 
One of the most recent studies regarding antibodies for potential therapeutic 
application was performed in 2012 by Tillotson et al to improve the affinity 
of a scFv targeting the transferrin receptor. Since this is a plasma membrane 
protein, detergent-solubilized membranes of HEK293 cells, ectopically 
expressing this receptor, were used as source of the antigen. A library of 
about 5x10^7 yeast cells was generated by random mutagenesis of the whole 
parental scFv and its screening led to the identification of various scFvs with 
3- to 7-fold improved affinities (from 0,38 to 0,18 nM) compared with the 
starting one.  
By yeast display, antibodies against some toxins have been engineered too, 
such as botulinum neurotoxin type A (Siegel et al, 2005). After a single cycle 
of error prone mutagenesis of two previously identified anti-toxin scFvs (Kd 
values of 0,8-0,9 nM), two mutants were identified with 45- and 37-fold 
improved affinities, respectively (20 pM).   
In 2005 Rajpal et al succeeded in generating improved versions of 
adalimumab (Kd 1 nM), an anti tumor necrosis factor-α (TNF-α) antibody 
already approved for the treatment of rheumatoid arthritis. They generated 
yeast libraries by applying a sort of high-throughput mutagenesis involving 
all the residues of the six CDRs; in this way, they isolated novel variants 
whose affinities were between 500- and 870-fold higher than adalimumab. 
Remarkably, these scFvs showed a 15- to 30-fold improvement of in vitro 
TNF neutralization.  
Yeast display has been successfully used to improve affinity of a lot of 
proteins other than antibodies, such as T cell receptors (Buonpane et al, 2007; 
Buonpane et al, 2005), integrin I domain (Jin et al, 2006), epidermal growth 
factor (Cochran et al, 2006), natural killer cell receptor (Dam et al, 2003) and 
interleukin-2 (IL-2) (Rao et al, 2004). Affinity maturation is not the only 
application of YSD: its versatility has been also demonstrated in de novo 
selection of binders with specificity for a given target, epitope mapping, 
screening of cDNA libraries, identification of protein variants with improved 
production and stability (Pepper et al, 2008). 
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1.6.  Antibodies in cancer treatment 
Among all the FDA approved mAbs, many are used for cancer treatment, 
where they offer a variety of therapeutic solutions, being administered alone 
(“naked antibodies”) or as immunoconjugates (Carter, 2001, Chiavenna et al, 
2017).  
Naked antibodies are used to mask the ligand-binding site or the dimerization 
site of oncogenic receptors, thus preventing their activation. In addition, 
some antibody isotypes (IgG1 and IgG3) are also able to activate the 
antibody-dependent cellular cytotoxicity (ADCC) and the complement-
dependent cytotoxicity (CDC). These mechanisms involve natural killer 
(NK) cells and complement components, which are recruited by the antibody 
Fc effector domain on the cancer cell surface, inducing cell lysis (Clynes et 
al, 2000).  
The immunoconjugates are widely used to deliver other therapeutic 
molecules or compounds only to cancer cells, limiting or avoiding the off-
target effects of traditional chemotherapies which often damage healthy cells 
too (fig. 4). The immunoconjugates commonly vehicle cytotoxic molecules 
(toxins or radioactive isotopes), cytokines, killer cells or liposomes loaded 
with other drugs. They often carry enzymes which convert a prodrug in a 
toxic compound directly on cancer cell surface; alternatively, they are 
streptavidin-conjugated and used to capture a biotin-conjugated radioisotope 
only at the tumor site (multistep targeting). 
A similar principle is used for the retargeting of oncolytic viruses; through 
genetic manipulation, some molecules of the viral envelope, which are 
involved in the recognition of normal cells, are replaced by tumor-specific 
antibody fragments, enabling the viruses to infect and lysing only tumor cells 
(Campadelli-Fiume et al, 2016). 
Besides all these approaches, aimed to a direct destruction of cancer cells, an 
innovative antibody-based approach has emerged, whose purpose is to 
“awaken” the patient’s immune system to fight cancer. A deeper 
understanding of cancer biology has brought to light that tumor cells have 
developed a lot of strategies to block the immune surveillance, resulting in 
tumor growth and progression and so explaining the resistance to the 
traditional therapies (Dunn et al, 2002). 
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Fig. 4: applications of monoclonal antibodies in cancer treatment. In 
conventional anti-cancer treatments, mAbs are used alone (naked mAbs), to 
block oncogenic receptors and to activate antibody-dependent cellular 
cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). 
Alternatively, mAbs are used to carry a variety of toxic compounds with non-
specific activity only to tumor cells. ADEPT: Antibody-directed enzyme 
prodrug therapy. 
 
1.7.  Role of the immune surveillance in cancer progression and 
development of immune escape mechanisms 
The cancer immune surveillance is the mechanism used by the immune 
system to recognize and remove cancer cells from our body; it is activated by 
tumor-associated neoantigens that result from the accumulation of mutations 
in various genes, due to the high genomic instability of cancer cells 
(Lawrence et al, 2013). The neoantigens are presented on the cell surface in 
complex with the Major Histocompatibility Complex-class I (MHC I) and 
then recognized by T cells as non-self-antigens (Snyder et al, 2015; Sensi et 
al, 2006); as result, the adaptive immune system is activated in order to kill 
cancer cells. 
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Among the several strategies developed by tumors to escape the immune 
surveillance, the one arousing the greatest therapeutic interest is the 
upregulation of molecules that activate the immune checkpoints (Pennock et 
al, 2015), a group of pathways which suppress T cell functions. Considering 
that these molecules are showed on cancer cell surface, they can be easily 
blocked by mAbs and so they have become an attractive therapeutic target. 
This is not the only strategy adopted by tumors to evade immunity. Another 
common escape mechanism is the impairment of the MHC I antigen 
presentation or of the endoplasmic reticulum and Golgi epitope processing, 
through genetic and epigenetic alterations (Fruci et al, 2012; Seliger et al, 
2002). In fact, a reduced expression of proteins associated with the 
immunoproteasome, such as the subunits low-molecular-weight protein 2 and 
7 (LMP-2 and LMP-7), or with the endoplasmic reticulum, for example the 
transporter associated with antigen presentation (TAP), has been reported in 
some tumors and cancer cell lines (Seliger et al, 1996; Alpan et al, 1996; 
Pandha et al, 2007). 
At last, tumors can evade the immune system by secreting 
immunosuppressive mediators that are able to inhibit the maturation and/or 
activation of tumor infiltrating immune cells. These effects are mainly due to 
the constitutive activation of the signal transducer and activator of 
transcription 3 (STAT3) pathway observed in many cancers (Wang et al, 
2004), which leads to the production of vascular endothelial growth factor 
(VEGF), IL-10, IL-6 and transforming growth factor-β (TGF-β) (Johnson et 
al, 2007; Liu et al, 2012). These molecules block NK and granulocyte 
effector functions, impair dendritic cell (DC) differentiation (Wang et al, 
2004) and promote the commitment of immature myeloid cells into myeloid 
suppressor cells, i.e. a subset of cells that inhibit T lymphocyte functions 
(Gabrilovich et al, 2009; Gabrilovich et al, 2012).  
 
 
1.8.  The immune checkpoints - the PD-1/PD-L1 pathway and its 
role in the regulation of T cell functioning  
The activity of T cells, which have a central role in the adaptive immunity 
against cancer, is regulated through a balance between activating and 
inhibitory stimuli generating from two different groups of surface receptors. 
The activating stimuli are also called co-stimulatory signals; they are 
necessary for activation of naïve T cells after the binding of the T cell 
receptor (TCR) to the MHC I-peptide complex. The co-stimulatory receptors 
are grouped into two main families. The first is the B7/CD28 family, which 
includes CD28, the inducible costimulator (ICOS) and the B- and T-
lymphocyte attenuator (BTLA); among them, the best characterized receptor 
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is CD28, which is activated upon binding of B7-1 (CD80) and B7-2 (CD86) 
expressed on antigen presenting cells (APCs). CD28 co-stimulation leads to 
cell cycle progression and increases cell metabolism through the activation of 
PI3K/AKT pathway.  
The other main group is the tumor necrosis factor receptor (TNFR) family. 
The members of this group, which includes CD40, CD27, CD30, OX40, 4-
1BB and the glucocorticoid-induced TNFR-related gene (GITR), share a 
common T cell activation mechanism that is the stimulation of the nuclear 
factor-kB (NF-kB), with the consequent increase in expression of pro-
inflammatory genes.  
The signaling pathways that negatively regulate T cell function are called 
immune checkpoints and play a key role in two main mechanisms. The first 
is the peripheral tolerance (Fife et al, 2008), a process that blocks the self-
reactive T cells that escape from negative selection in the thymus; the second 
is the switching-off of T lymphocyte effector functions that normally occurs 
during an immune response. This group of receptors includes the cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4), the programmed death-1 (PD-1) 
receptor, the lymphocyte-activation gene 3 (LAG-3) and the T cell 
immunoglobulin 3 (TIM-3); among them, CTLA-4 and PD-1 pathways are 
the best characterized ones.  
CTLA-4 is expressed on T cells as a response to T cell activation and 
competes with the co-stimulatory receptor CD28 for the binding to the B7 
ligand. CTLA-4 signaling is mediated by the intracellular phosphatase PP2A, 
which switches-off the Akt pathway, previously activated by co-stimulatory 
receptors. 
PD-1 (also known as CD279) is a monomeric transmembrane protein of the 
Ig superfamily and its sequence shares 64% of homology with its murine 
orthologue (Lin et al, 2008). PD-1 extracellular region contains an IgV-like 
domain that interacts with the Ig domains of its ligands, programmed death 
ligand-1 and -2 (PD-L1 and PD-L2); the cytoplasmic tail has no intrinsic 
enzymatic activity but contains two tyrosine-based signaling domains, called 
immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor 
tyrosine-based switch motif (ITSM), whose tyrosine residues are 
phosphorilated and recruit PD-1 downstream effectors to the plasma 
membrane (Riley, 2009).   
PD-L1 (also called B7-H1 or CD274) has 70% sequence identity with its 
murine orthologue, which allows in vitro cross reactivity between murine and 
human PD-1 and PD-L1 (Lin et al, 2008). Unlike its receptor, PD-L1 
extracellular region contains two Ig domains, an N-terminal IgV-like domain 
that binds to PD-1 and an IgC-like one. It is a monomeric protein, but 
crystallographic analyses showed that it can exists in solution as dimeric 
complex too, although it is not clear the role of this complex in vivo in 
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immune system functioning (Chen et al, 2010). The other ligand PD-L2 (B7-
DC or CD273) was discovered more recently than PD-L1 (Latchman et al, 
2001). These two ligands have the same structure and share 40% amino acid 
identity.  
All downstream effects of PD-1 are mediated by the Src homology 
phosphatase 2 (SHP-2), which is recruited via a Src homology 2 (SH-2) 
domain to the phosphorylated ITIM motif (Zhang et al, 2004). Among SHP-2 
substrates, we find the lymphocyte-specific protein tyrosine kinase (Lck) and 
the zeta-chain-associated protein kinase 70 (ZAP-70), which are the main 
effectors of the TCR; they are inactivated through dephosphorilation by SHP-
2, blocking the TCR signaling and consequently downregulating the target 
genes that promote T cell effector functions (Sheppard et al, 2004). PD-1 
activation also impairs the PI3K/Akt and Ras/MAPK pathways (Parry et al, 
2005), (fig. 5). The blockade of the PI3K/Akt pathway mainly affects glucose 
metabolism, by reducing the glycolytic enzyme activity and the expression of 
glucose transporters on T cell membrane; as a consequence, T cells are 
deprived of the main source of energy necessary for their growth and cell 
division. These metabolic changes also alter their differentiation (Chang et al, 
2013; Patsoukis et al, 2015), promoting the switch from a T effector to a Treg 
and T-exhausted phenotype, which are responsible for the suppression of the 
immune response. On the other hand, the PD-1 mediated inhibition of the 
Ras/MAPK signaling, which is involved in the positive regulation of the cell 
cycle, stimulates T cells to enter G0 phase (Patsoukis et al, 2012); as a result, 
T cell proliferation is blocked.   
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Fig. 5: schematic representation of PD-1 intracellular pathway. Upon 
engagement of PD-1 (in blue, on T cell surface) by PD-L1 (in light blue on 
APC or tumor cell surface), the SHP1/SHP2 phosphatases are recruited to 
PD-1 effector domains (in yellow) and then activated. These proteins affect 
the function of several targets: the complex of the T cell receptor (TCR, on 
the right), the Ras/MAPK and PI3K pathways and the basic leucine zipper 
transcriptional factor ATF-like (BATF). Boxes A, B, C, D and E summarize 
the resulting molecular and cellular alterations. 
 
 
  Introduction 
21 
 
1.9.  Impairment of PD-1/PD-L1 pathway in cancer 
PD-1 expression is limited to immune cells, both lymphoid and myeloid 
lineages (T and B lymphocytes, NK cells, monocytes and DCs) (Keir et al, 
2008), in which it is expressed at a low basal level. During the immune 
response, it is upregulated by the cytokines IL-2, IL-7, IL- 15, IL-21 and 
interferon-α (IFN-α) (Kinter et al, 2008; Cho et al 2008) and by a prolonged 
stimulation of T and B cell receptors (Freeman et al, 2006).  
On the contrary, PD-L1 expression is not restricted to immune cells; in 
healthy conditions, it is expressed in many other tissues to protect themselves 
from immune attacks; PD-L1 is found at high levels in thymus cortex, lung, 
heart muscle, placenta, liver, mesenchymal stem cells and vascular 
endothelium; lower PD-L1 levels are found in pancreatic islets, astrocytes, 
neurons, keratinocytes (Keir et al, 2008), cornea and retina (Hori et al, 2006; 
Sugita et al, 2009). A lot of cytokines produced during the immune response, 
such as IL-2, IL-10, IL-7, IL-15, IL-21 and IFN-γ, upregulate PD-L1 in 
immune cells. 
Interestingly, PD-L1 is expressed at high levels in many kinds of hematologic 
and solid tumors, due to the constitutive activation of some oncogenic 
pathways that positively control its transcription, in particular STAT3 
(Marzek et al, 2008), PI3K/Akt and PI3K/mTOR pathways (Crane et al, 
2009). Moreover, the IFN-γ present in the tumor microenvironment can 
induce PD-L1 expression too. IFN-γ is secreted by tumor infiltrating T 
lymphocytes activated by tumor antigens during the early stages of cancer 
development; in addition to its pro-inflammatory activity, this cytokine 
upregulates PD-L1 in tumor cells and so it is responsible for the suppression 
of T cell antitumor activity (fig. 6) (Taube et al, 2012). High PD-L1 levels 
have been detected not only on cancer cells, but also on the surface of the 
immune and non-immune cells that form the tumor microenvironment, that is 
macrophages, DCs, stromal fibroblasts and the endothelium of tumor 
neovasculature (fig. 7). 
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Fig. 6: mechanism of PD-L1 mediated inhibition of T cells by tumors. T 
cells activated by tumor- specific antigens, proliferate and produce cytokines. 
These inflammatory stimuli upregulate PD-L1 in tumor cells; its binding to 
PD-1 expressed on the same T cells negatively regulate their proliferation 
and effector functions, preventing cancer cells from killing. 
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Fig. 7: PD-L1 and PD-L2 expression in the tumor microenvironment. 
Cancer cells (in black), stromal fibroblasts, tumor-infiltrating myeloid-
derived suppressor cells (MDSC) and macrophages (particularly M2 subtype) 
show PD-1 ligands on their surface (in orange). This promotes the 
engagement of infiltrating T lymphocytes and their differentiation into Treg 
cells, with immunosuppressive activity. 
 
PD-L2 is expressed only on stromal cells of thymus medulla, macrophages, 
bone marrow derived mast cells, peritoneal B1 cells and activated DCs 
(Zhong et al, 2007). In DCs its expression is positively regulated by IL-4 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Selenko-
Gebauer et al, 2003). PD-L2 is also expressed in various types of human 
tumors (Rozali et al, 2012); however, it has not received as much attention as 
PD-L1 and its role in modulating antitumor immunity is less clear. 
The overexpression of PD-L1 on cancer cells (or cells of the tumor stroma) is 
used by tumors as a mechanism of escape of the immune response, to protect 
themselves from killing by T cells. The binding of PD-L1 to its receptor PD-
1 expressed on the tumor infiltrating lymphocytes activates the PD-1 
checkpoint, blocking the downstream T cell pathways involved in cytotoxic 
response against the tumor.  
The binding of PD-L1 to PD-1 is able to transduce signals not only in T cells, 
but in cancer cells too (Azuma et al, 2008). In fact, PD-L1 can act as PD-1 
receptor in tumor cells, transmitting them anti-apoptotic signals which 
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enhance their resistance to apoptosis induced by both immune effectors and 
proapoptotic drugs. 
 
 
1.10. Targeting of immune checkpoints with mAbs  
Considering that the activation of immune checkpoints is a common 
mechanism used by tumors to escape the immune surveillance, there has been 
a great interest in developing therapeutic strategies that blocked these 
pathways. A great promise for cancer treatment is represented by the 
monoclonal antibodies that recognize the checkpoint receptors or ligands, 
preventing them to bind to each other. In this way, the inhibitory signals 
transduced to immune cells are blocked, so that they are reactivated to 
recognize and kill tumor cells (fig. 8).  
 
 
 
Fig. 8: effects of the immune checkpoint blockade by monoclonal 
antibodies. The binding of therapeutic mAbs to immune checkpoint 
components (anti CTLA-4, anti PD-1 and anti PD-L1, in purple, light blue 
and grey, respectively) removes the negative stimuli to T cell proliferation. In 
this way, T cells are re-activated to proliferate and recognize cancer cells. If 
used in combination, these antibodies can have a sinergistic effect.  
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A lot of monoclonal antibodies have been designed to target components of 
both activating and inhibitory pathways for the treatment of many solid 
tumors and hematologic malignancies (Peggs et al, 2009) (fig. 9). Many of 
these mAbs are in different phases of clinical development, few others have 
already been approved by FDA. The most targeted checkpoints are CTLA-4 
and PD-1.  
Ipilimumab, an anti CTLA-4 IgG1, was the first checkpoint inhibitor 
approved by FDA; it entered clinics in 2011 in USA and Europe for the 
treatment of unresectable or metastatic melanoma (Wolchok et al, 2013). 
Other clinical trials are ongoing for the evaluation of its therapeutic efficacy 
in combination regimens with other checkpoint inhibitors, in advanced 
melanoma cases which had not received any previous treatment (Larkin et al, 
2015; Hodi et al, 2016). Ipilimumab, in combination with chemotherapy or 
other mAbs, is in advanced clinical trial also for the first line treatment of 
other solid tumors, particularly small and non-small cell lung cancer (SCLC 
and NSCLC) (Lynch et al, 2012; Reck et al, 2013; Antonia et al, 2016). 
Given the therapeutic success of CTLA-4 blockade, other checkpoints have 
been targeted, particularly the PD-1/PD-L1 checkpoint. Among the 
antibodies developed to target this pathway, pembrolizumab and nivolumab 
have already been approved by FDA, while the others are in advanced 
clinical trials.  
Pembrolizumab, a humanized IgG4, was the first anti PD-1 mAb to be 
approved by the FDA in 2014 for the treatment of metastatic melanoma that 
was not responsive to previous treatment with ipilimumab or with BRAF 
inhibitors (in tumors with BRAF mutations) (Robert et al, 2015). In 2015, the 
FDA extended its approval also to NSCLC (Garon et al, 2015).   
Nivolumab is a fully human IgG4 in clinical use for the treatment of 
melanoma since 2014, with the same therapeutic indications as 
pembrolizumab (Weber et al, 2015). It demonstrated a good response rate in 
both untreated and previously treated metastatic melanoma cases. Very good 
results were obtained when nivolumab was used in combination with 
ipilimumab; in fact, in a phase III trial, the group of advanced melanoma 
patients treated with both the antibodies showed a 5-fold higher response rate 
than the group treated with ipilimumab alone (Postow et al, 2015). The 
clinical efficacy of nivolumab was also proven in squamous and metastatic 
NSCLC, renal cell carcinoma (RCC), head and neck cancer and Hodgkin 
lymphoma; in this last case the response rate was even 87% (Ansell et al, 
2015).  
Interestingly, a higher clinical response rate to these two anti PD-1 mAbs was 
observed when tumors expressed high levels of its ligand PD-L1 (Weber et 
al, 2015). The same result was also obtained after treatment with 
MPDL3280A (atezolizumab), a human anti PD-L1 IgG1 that was tested on 
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277 patients affected by various types of advanced incurable cancer (NSCLC, 
melanoma, RCC, colorectal cancer, gastric cancer and head and neck 
squamous cell carcinoma) (Herbst et al, 2014). Tumors that upregulated PD-
L1, especially on tumor infiltrating immune cells, showed a better response 
than those tumors in which no or very low PD-L1 levels were detected. This 
studies support the hypothesis that PD-L1 expression within the tumor could 
be considered as a predictive biomarker of good outcomes upon treatment 
with PD-1/PD-L1 inhibitors.   
 
 
 
 
 
 
Fig. 9: spectrum of mAbs developed against activating or inhibiting T 
cell surface receptors to reactivate the antitumor immune response. 
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